Enhancing thoracic oncology in Armenia: Impact of the implementation of an expert-guided virtual multidisciplinary tumor board.
Authors: Zohrabyan Davit , Karapetyan Nune , Tamamyan Gevorg , Safaryan Liana , Bardakhchyan Samvel , Karamyan Sona , Ghayamyan Meri , Khachatryan Mariam , Danielyan Samvel , Rushanyan Marine , Mkrtchyan Gohar , Harutyunyan Martin , Sargsyan Amalya , Mailyan Mariam , Gharadaghyan Hovsep , Mkhitaryan Benik , Avagyan Hayk , Baloyan Elen , Shaverdian Narek , Kalemkerian Gregory Peter 
Published: July 2024

e13808 Background: The importance of expert-guided multidisciplinary tumor boards (MDTs) in the management of patients with complex malignancies is well established. Modern global telecommunication platforms allow for holding specialized virtual MDT discussions led by international experts even in limited-resource settings. The creation of such a group is of high importance for Armenia given the high incidence and increasing complexity of thoracic malignancies. We describe the initial impact of the implementation of the Thoracic Tumors Working Group (TTWG) of Armenia from August 2022 through January 2024. Methods: The TTWG of Armenia is an MDT comprised of medical oncologists, radiation oncologists, thoracic surgeons, pathologists, and radiologists. The group was formed under the Immune-Oncology Research Institute in August 2022 to discuss the management of patients with complicated thoracic malignancies. For each case, the clinical history, imaging, pathologic findings, and patient management plans are discussed. Updates on treatment paradigms and ongoing clinical trials are also reviewed. The MDTs are held biweekly via the Zoom platform under the supervision of international experts in thoracic oncology. Recordings of MDTs were reviewed to retrospectively identify case characteristics and the impact on patient management. Results: From August 2022 through January 2024, 89 cases were discussed during 33 TTWG MDTs. On average, each MDT was attended by 14 physicians and trainees in Armenia, and by two international experts in thoracic medical and radiation oncology. Median meeting length was 55 minutes with a median of 3 cases presented. Diagnoses included lung adenocarcinoma (n=31, 37.3%), squamous cell lung carcinoma (n=15, 18.0%), neuroendocrine tumors (n=16, 19.3%), small cell lung cancer (n=16, 19.3%), and thymic epithelial tumors (n=6, 7.3%). All disease stages were represented: I 3.7%, II 4.9%, III 31.7%, and IV 47.9%. The male-to-female ratio was 3.6:1 and the median age was 63 years (range: 29-76). Based on MDT discussion, the pre-MDT diagnosis was confirmed in 95.5% (n=85) of patients with down-staging in 3.4% (n=3). The proposed pre-MDT treatment plan was significantly altered in 42.7% (n=38) of patients. Additional studies, mainly PET/CT, bronchoscopy, and broader molecular profiling were recommended for 29.2% (n=26) of patients. Follow-up discussions were held for 7.9% (n=7) of patients based on information arising from prior MDT discussions. The TTWG of Armenia continues to be active. Conclusions: Our initial data suggest that the TTWG of Armenia has had a meaningful influence on patient management by providing access to specialty-expert care and physician education. The impact on patient outcomes will continue to be assessed. The TTWG of Armenia can serve as a model to improve outcomes in other resource-limited settings.